Literature DB >> 26822727

Brain Region-Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease).

J P Dyke1, D Sondhi2, H U Voss3, K Yohay4, C Hollmann2, D Mancenido2, S M Kaminsky2, L A Heier3, K D Rudser5, B Kosofsky4, B J Casey6, R G Crystal2, D Ballon7.   

Abstract

BACKGROUND AND
PURPOSE: Late infantile neuronal ceroid lipofuscinosis (CLN2 disease) is a uniformly fatal lysosomal storage disease resulting from mutations in the CLN2 gene. Our hypothesis was that regional analysis of cortical brain degeneration may identify brain regions that are affected earliest and most severely by the disease.
MATERIALS AND METHODS: Fifty-two high-resolution 3T MR imaging datasets were prospectively acquired on 38 subjects with CLN2. A retrospective cohort of 52 disease-free children served as a control population. The FreeSurfer software suite was used for calculation of cortical thickness.
RESULTS: An increased rate of global cortical thinning in CLN2 versus control subjects was the primary finding in this study. Three distinct patterns were observed across brain regions. In the first, subjects with CLN2 exhibited differing rates of cortical thinning versus age. This was true in 22 and 26 of 34 regions in the left and right hemispheres, respectively, and was also clearly discernable when considering brain lobes as a whole and Brodmann regions. The second pattern exhibited a difference in thickness from healthy controls but with no discernable change with age (9 left hemispheres, 5 right hemispheres). In the third pattern, there was no difference in either the rate of cortical thinning or the mean cortical thickness between groups (3 left hemispheres, 3 right hemispheres).
CONCLUSIONS: This study demonstrates that CLN2 causes differential rates of degeneration across the brain. Anatomic and functional regions that degenerate sooner and more severely than others compared with those in healthy controls may offer targets for directed therapies. The information gained may also provide neurobiologic insights regarding the mechanisms underlying disease progression.
© 2016 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2016        PMID: 26822727      PMCID: PMC4907890          DOI: 10.3174/ajnr.A4669

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  27 in total

1.  Brain development during childhood and adolescence: a longitudinal MRI study.

Authors:  J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport
Journal:  Nat Neurosci       Date:  1999-10       Impact factor: 24.884

2.  Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.

Authors:  S Worgall; M V Kekatpure; L Heier; D Ballon; J P Dyke; D Shungu; X Mao; B Kosofsky; M G Kaplitt; M M Souweidane; D Sondhi; N R Hackett; C Hollmann; R G Crystal
Journal:  Neurology       Date:  2007-08-07       Impact factor: 9.910

3.  A comparison of voxel and surface based cortical thickness estimation methods.

Authors:  Matthew J Clarkson; M Jorge Cardoso; Gerard R Ridgway; Marc Modat; Kelvin K Leung; Jonathan D Rohrer; Nick C Fox; Sébastien Ourselin
Journal:  Neuroimage       Date:  2011-05-26       Impact factor: 6.556

4.  The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH.

Authors:  L Lin; I Sohar; H Lackland; P Lobel
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

Review 5.  Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: An overview.

Authors:  D G Birch
Journal:  Mol Genet Metab       Date:  1999-04       Impact factor: 4.797

Review 6.  Genetics of the neuronal ceroid lipofuscinoses (Batten disease).

Authors:  Sara E Mole; Susan L Cotman
Journal:  Biochim Biophys Acta       Date:  2015-05-27

Review 7.  Neuronal ceroid lipofuscinoses: classification and diagnosis.

Authors:  K E Wisniewski; E Kida; A A Golabek; W Kaczmarski; F Connell; N Zhong
Journal:  Adv Genet       Date:  2001       Impact factor: 1.944

8.  Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I.

Authors:  D J Vines; M J Warburton
Journal:  FEBS Lett       Date:  1999-01-25       Impact factor: 4.124

9.  Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging.

Authors:  J P Dyke; D Sondhi; H U Voss; D C Shungu; X Mao; K Yohay; S Worgall; N R Hackett; C Hollmann; M E Yeotsas; A L Jeong; B Van de Graaf; I Cao; S M Kaminsky; L A Heier; K D Rudser; M M Souweidane; M G Kaplitt; B Kosofsky; R G Crystal; D Ballon
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

Review 10.  Neuronal ceroid lipofuscinoses.

Authors:  Anu Jalanko; Thomas Braulke
Journal:  Biochim Biophys Acta       Date:  2008-11-24
View more
  9 in total

Review 1.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

2.  Expanding the Neuroimaging Phenotype of Neuronal Ceroid Lipofuscinoses.

Authors:  A Biswas; P Krishnan; A Amirabadi; S Blaser; S Mercimek-Andrews; M Shroff
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

Review 3.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

4.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

5.  Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2.

Authors:  Dolan Sondhi; Stephen M Kaminsky; Neil R Hackett; Odelya E Pagovich; Jonathan B Rosenberg; Bishnu P De; Alvin Chen; Benjamin Van de Graaf; Jason G Mezey; Grace W Mammen; Denesy Mancenido; Fang Xu; Barry Kosofsky; Kaleb Yohay; Stefan Worgall; Robert J Kaner; Mark Souwedaine; Bruce M Greenwald; Michael Kaplitt; Jonathan P Dyke; Douglas J Ballon; Linda A Heier; Szilard Kiss; Ronald G Crystal
Journal:  Sci Transl Med       Date:  2020-12-02       Impact factor: 17.956

6.  Computed tomography provides enhanced techniques for longitudinal monitoring of progressive intracranial volume loss associated with regional neurodegeneration in ovine neuronal ceroid lipofuscinoses.

Authors:  Katharina N Russell; Nadia L Mitchell; Nigel G Anderson; Craig R Bunt; Martin P Wellby; Tracy R Melzer; Graham K Barrell; David N Palmer
Journal:  Brain Behav       Date:  2018-08-23       Impact factor: 2.708

Review 7.  Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview.

Authors:  Alessandro Simonati; Ruth E Williams
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003

8.  Natural history of MRI brain volumes in patients with neuronal ceroid lipofuscinosis 3: a sensitive imaging biomarker.

Authors:  Jan-Niklas Hochstein; A Schulz; M Nickel; S Lezius; M Grosser; J Fiehler; J Sedlacik; U Löbel
Journal:  Neuroradiology       Date:  2022-06-14       Impact factor: 2.995

9.  Extracellular Vesicles as Drug Carriers for Enzyme Replacement Therapy to Treat CLN2 Batten Disease: Optimization of Drug Administration Routes.

Authors:  Matthew J Haney; Yuling Zhao; Yeon S Jin; Elena V Batrakova
Journal:  Cells       Date:  2020-05-20       Impact factor: 7.666

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.